Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NCEH1 | Q6PIU2 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23499947 | 0.86 | CNR2 (0.59) | MAPTKDM4EHPGDPOLBALDH1A1 | |
| SCHEMBL23499953 | 0.85 | MAPT (0.58) | MAPTKDM4EHPGDPOLBALDH1A1 | |
| SCHEMBL3357585 | 0.84 | NCEH1 (0.65) | MAPTKDM4EHPGDPOLBALDH1A1 | |
| SCHEMBL30676839 | 0.84 | NCEH1 (0.65) | MAPTKDM4EHPGDPOLBALDH1A1 | |
| SCHEMBL979842 | 0.84 | CA12 (0.58) | MAPTKDM4EHPGDPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL5403782 | 0.83 | CA12 (0.56) | MAPTKDM4EHPGDPOLBALDH1A1 | |
| SCHEMBL10617741 | 0.83 | NCEH1 (0.57) | MAPTKDM4EHPGDPOLBALDH1A1 | |
| SCHEMBL10966660 | 0.83 | MAPT (0.55) | MAPTKDM4EHPGDPOLBALDH1A1 | |
| SCHEMBL3915104 | 0.83 | NCEH1 (0.70) | MAPTKDM4EHPGDPOLBALDH1A1 | |
| SCHEMBL3997233 | 0.83 | MAPT (0.55) | MAPTKDM4EHPGDPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4407815-A | AMINO ACID DERIVATIVE ANTIBIOTICS | BEECHAM GROUP LIMITED (GB) | 1983-10-04 | — | — | US | claimed |
| WO-2023277630-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | 주식회사 티움바이오 | 2023-01-05 | — | — | WO | disclosed |
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| CN-107438599-B | Targeted Notch pathway inhibitors | 豪夫迈·罗氏有限公司 | 2021-12-10 | — | — | CN | disclosed |
| US-20200102318-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-04-02 | — | — | US | disclosed |
| CN-107382770-B | A method of alpha-amido oximido ether compound is synthesized by N- alkoxy amide and 2H- aziridine | 浙江大学 | 2019-07-09 | — | — | CN | disclosed |
| CN-107382770-A | A kind of method that α amino oximido ether compounds are synthesized by N alkoxy amides and 2H aziridine | 浙江大学 | 2017-11-24 | — | — | CN | disclosed |
| US-20170233398-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. | 2017-08-17 | — | — | US | disclosed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| EP-0046363-B1 | PROCESS FOR THE PREPARATION OF 2-THIO PENEM DERIVATIVES AND INTERMEDIATES THEREFOR | BEECHAM GROUP PLC (GB) | 1984-11-14 | — | — | EP | disclosed |
| EP-0034443-B1 | BETA-LACTAM ANTIBACTERIAL COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1984-09-26 | — | — | EP | disclosed |
| US-4463010-A | 1-Aza-[3.2.0]-bicycloheptane-2-carboxylic acid, ester or salt thereof | BEECHAM GROUP P.L.C. (GB) | 1984-07-31 | — | — | US | disclosed |
| US-4387051-A | β-Lactam antibiotics, their preparation and their use in pharmaceutical compositions | BEECHAM GROUP LIMITED (GB) | 1983-06-07 | — | — | US | disclosed |
| EP-0073100-A1 | Beta-lactam compounds, their preparation and their use | BEECHAM GROUP PLC (GB) | 1983-03-02 | — | — | EP | disclosed |
| EP-0067518-A1 | Modified beta-lactam compounds | BEECHAM GROUP PLC (GB) | 1982-12-22 | — | — | EP | disclosed |
| EP-0046363-A1 | Process for the preparation of 2-thio penem derivatives and intermediates therefor | BEECHAM GROUP PLC (GB) | 1982-02-24 | — | — | EP | disclosed |
| US-4304853-A | Method of determination for proteases and antiproteases | JOZEFONVICZ MARCEL | 1981-12-08 | — | — | US | disclosed |
| EP-0034443-A2 | Beta-lactam antibacterial compounds, their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1981-08-26 | — | — | EP | disclosed |
| EP-0028497-A1 | Beta-lactam antibiotics, their preparation and their use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | MAPT 3391/4885KDM4E 2478/4885HPGD 2574/4885 |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | ESRRB, ESRRA, ESR2 | MAPT 4637/4885KDM4E 3063/4885HPGD 836/4885 |
| US-20170233398-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, SCN3A | MAPT 3111/4885KDM4E 3099/4885HPGD 1585/4885 |
| US-20200102318-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, CACNA1A | MAPT 3391/4885KDM4E 2478/4885HPGD 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.